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Purpose: The aim of the study was to assess perinatal
outcome of pregnancy burdened with maternal addiction in
comparison with an unselected population from a European
transition country. Materials and Methods: Data on
pregnancies complicated by illicit drug abuse (n = 85)
managed during a 10-year period (1997 - 2007) at Split
University Hospital were analyzed. Data on the type of
drug, course of gestation and labor, and on perinatal outcome
were considered. Data on all non-dependence pregnancies
recorded during the study period were used as a control
group. Results: During the study period, there were 85
dependence-complicated pregnancies (0.2%). Use of heroin
alone during pregnancy was recorded in 51 women (50%),
methadone alone in 6 (7%), and a combination of heroin
and methadone in 9 (11%). Premature delivery was signi-
ficantly more common in the group of pregnant addicts
(21% vs. 6%); 49% of pregnant addicts were carriers of
hepatitis C virus (HCV) and 14% of hepatitis B virus (HBV).
Neonatal abstinence syndrome developed in 61 infants (7%)
born to addicted mothers. There were 4 cases (4.6%) of
early neonatal death; 7 neonates had 5-minute Apgar score
7 (8%); 29 neonates had low birth weight for age (33%);
and 7 neonates had congenital anomalies (8%). The risk of
various congenital anomalies was 3-fold in the group of
children born to addicted mothers. Conclusion: Addiction
pregnancies present a small but high-risk group according to
perinatal outcome. Appropriate obstetric and neonatal care
can reduce the rate of complications in these pregnancies
and improve perinatal outcome.
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INTRODUCTION
Substance abuse has crossed social, economic,
and geographical borders, and remains one of the
major problems that modern society is facing
worldwide. The prevalence of substance abuse in
young adults of both genders has increased
markedly over the past 20 years. Nearly 90% of
drug-abusing women are of childbearing age.
1
However, the exact number of drug-dependent
women is unknown because the statistics relies
heavily on voluntary patient disclosure.
2 Some
women tend to keep the use of illicit drugs from
gynecologists for fear of stigmatization and
discrimination, therefore, the symptoms induced
by maternal dependence cannot always be
recognized.
3 In addition, it is difficult to identify
the proportion of pregnancies in addicts ter-
minated by spontaneous or induced abortion.
4
The number of heroin addicts of fertile age in
Croatia has been estimated to be 4,500, of which
some 250 give birth to 1 child per year.
3 Heroin
alone or in combination with methadone has been
used during the past decade by approximately
80% of addicted mothers in Croatia and
worldwide.
3,5 In 80% of cases, opiate addicts take
at least 1 more drug or psychoactive substance
along with heroin and more than 50% suffer from
psychiatric comorbidity.
3 Major health problems
associated with high-risk lifestyle observed in
non-pregnant illicit opiate users are also observed
in pregnant users. These include poor nutritional
habits, increased incidence of infectious and
sexually transmitted diseases, other substance
abuse, and poor antenatal care.
6 These factors are
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likely to contribute to an increased risk of obstetric
complications including placental insufficiency,
miscarriage and intrauterine death, and neonatal
morbidity.
6-8 In utero drug exposure can have a
severe impact on not only the development of the
fetus but also the child later in life.
9 Perinatal
death, prematurity, fetal growth retardation,
neonatal abstinence syndrome (NAS), and a wide
variety of other perinatal complications have been
frequently observed in the offspring of heroin-
addicted women but it is unclear how much these
effects are due to fetal heroin exposure or to
generally poor health and limited prenatal care in
these women.
6,10-13
We analyzed drug abuse during pregnancy in
the Split-Dalmatia County, Croatia. The purpose
of the study was to compare perinatal outcome
between heroin-exposed and unexposed pre-
gnancies in a European transition country where
heroin alone or with methadone is a predominant
illicit drug in not only the population of pregnant
women but also society in general.
MATERIALS AND METHODS
In this retrospective cohort study, data on
heroin, methadone, and polydrug addicted
pregnant women admitted for delivery to the
university Department of Obstetrics and
Gynecology, Split University Hospital, in Split,
Croatia, during a 10-year period were analyzed.
During the study period from January 1, 1997, to
January 1, 2007, there were 43,181 deliveries with
43,529 newborns, including 371 twin pregnancies
(0.860%) and 5 triplet pregnancies (0.0116%).
Stillbirths were excluded because there was no
such case in the study group of addiction pre-
gnancies. Records of 85 pregnant women with 86
neonates (1 twin pregnancy) found to have used
illicit drugs during pregnancy were selected from
the maternal and neonatal files kept at the
department. In 62 subjects (73%), testing was
performed after they admitted drug addiction
during pregnancy, delivery, or after delivery. Data
on the type of drug, course of gestation and labor,
and overall perinatal outcome were considered.
Gestational age was calculated from the onset of
the last menstruation and corrected according to
ultrasonography (US) finding when the difference
exceeded 1 week. In children born to addicted
mothers, urine toxicology (Abbott Laboratories
Diagnostics Division, IL, USA) for dependence
substances, 5-minute Apgar score, and NAS score
according to Finnegan were performed.
14 Our own
standards were used to evaluate fetal growth from
birth weight according to gestational age and
maternal parity and by use of ponderal index (PI
(g/cm
3) = weight (g) × 100/length (cm
3).
15,16
The data obtained were compared with a con-
trol group that included all non-addicted women
admitted for delivery during the study period (n
= 43,096) and their newborns (n = 43,529).
Statistical data analysis was performed using
SPSS 10 statistical software, t-test, Mann-Whitney
test for quantitative data, and 
2-test and odds
ratio for qualitative data. The level of statistical
significance was set at p < 0.05.
RESULTS
During the 10-year study period, there were 85
addiction pregnancies (0.2%) with 86 newborns
(0.2%). General characteristics of both study and
control groups of pregnant women and their
pregnancies are shown in Table 1.
In the study group of 85 pregnant addicts,
heroin was used by 51 (60%), methadone alone by
6 (7%), and a combination of heroin and methadone
by 9 (11%). Of other dependence substances,
benzodiazepines in combination with heroin
and/or methadone were most commonly used, as
reported by 15 women (19%) (Table 2).
Data obtained on the course of labor, labor
complications, and sexually transmitted diseases
in the study and control group of women showed
statistically significant differences. Statistically
significant between-group differences were
observed in all parameters assessed except for the
rate of premature rupture of membranes (PROM;
p = 0.448), rate of cesarean section (p = 0.122),
gestational age at delivery (p = 0.509), and gesta-
tional age at preterm delivery (p = 0.304). Preterm
delivery was significantly more frequent in the
group of addicted women (21% vs. 6%), yielding
a relative risk of 3.45 (Table 3).
Neonatal outcome data showed that newbornsNeonatal Effects of Maternal Substance Abuse
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of lower vitality were born more frequently to
addicted mothers. In these newborns, the risk of
Apgar score <7 was 6-fold that of the control group.
Children born to addicted mothers generally
had lower birth weight with a 7-fold risk of small
for gestational age (SGA) newborns. The risk of
various congenital anomalies was 4-fold in the
group of children born to addicted mothers.
Congenital cardiac defects were most common,
including ventriculoseptal defect in 3 cases, and
transposition of great vessels and hypoplastic left
heart in 1 case each. Other anomalies included
small intestine malrotation, polydactyly, and
single umbilical artery in 1 case each. In the
neonates born to addicted mothers, the risk of
intracranial hemorrhage was 6-fold, of early
neonatal sepsis caused by Streptococcus agalactiae
8-fold, and of early neonatal death 11-fold that of
the control group (Table 4).
Five newborns died in the first week of life, 2
from asphyxia and prematurity, 2 from cardiac
defect, and 1 from early neonatal sepsis (Table 5).
In the children born to addicted mothers, the
length of hospital stay was approximately 50%
longer than in the control group children. NAS
developed in 61 neonates (71%) born to addicted
mothers with variation in manifestation according
to the substance of abuse taken by the mother; i.e.
heroin, methadone, heroin and methadone, or
some other dependence substances (Table 5).
Table 1. Main Maternal Characteristics and Pregnancy Data
Pregnant addicts
(n = 85)
Control group
(n = 43,096)
Risk ratio
(95% CI)
p value
Parity 1.13 ± 0.457 1.77 ± 0.949 < 0.001
No. of gynecologic examinations during
pregnancy (mean ± SD)
4.87 ± 3.2 8.43 ± 2.23 < 0.001
No. of US studies during pregnancy
(mean ± SD)
3.03 ± 1.99 5.58 ± 1.72 < 0.001
< 7 gynecologic examinations during
pregnancy, n (%)
55 (64.7%) 6,206 (14.4%) 11 (7 - 17) < 0.001*
< 3 US studies during pregnancy, n (%) 35 (41.2%) 1,465 (3.41%) 20 (13 - 31) < 0.001*
Body weight gain in pregnancy (kg)
(mean ± SD)
12.1 ± 5.4 14.8 ± 4.33 < 0.001
No. of women with weight gain < 9 kg, n (%) 18 (21%) 4,309 (10%) 2.4 (1.4 - 4.1) < 0.001*
Age (mean ± SD) (yrs) 27.6 ± 5.5 28.9 ± 4.6 0.011
US, ultrasonography.
*
2-test.
t-test.
Mann-Whitney test.
Table 2. Distribution of Pregnant Addicts according to Type of Opiate Used (n = 85)
Opiate type (route of intake) Pregnant women (n) %
Heroin (intravenous) 51 60
Heroin (intravenous or intranasal) and methadone (oral) 9 11
Methadone (oral) 6 7
Other dependence substances along with heroin and methadone, e.g.,
barbiturates, benzodiazepines, and marijuana (intravenous, oral)
19 22Mirjana Vucinovic, et al.
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Table 3. Intrapartum Complications and Sexually Transmitted Diseases
Pregnant addicts
(n = 85)
Control group
(n = 43,096)
Risk ratio
(95% CI)
p value
No. of preterm deliveries 18 (21%) 2,649 (6%) 4.1 (2.4 - 6.9) < 0.001*
Abruptio placentae (n) 0 215 (0.5%)
Gestational age at delivery (wks) 37.9 ± 2.3 38.4 ± 1.78 0.509
Gestational age in preterm deliveries (wks) 34.5 ± 2.2 33.7 ± 3.20 0.304
Premature rupture of membranes, n (%) 6 (7%) 2,253 (5%) 1.4 (0.6 - 3.2) 0.448*
Cesarean section, n (%) 7 (8%) 6,123 (14%) 1.85 (0.85 - 4.2) 0.112*
Hepatitis B 14 (16%) 861 (2%) < 0.001*
Hepatitis C 42 (49%) 17 (0.04%) < 0.001*
Hepatitis B + hepatitis C 9 (11%) 17 (0.04%) < 0.001*
HIV 0 0
HIV, human immunodeficiency.
*
2-test.
t-test.
Table 4. Neonatal Outcome
Neonates
Risk ratio
(95% CI)
p value Pregnant addicts
(n = 86)
Control group
(n = 43,529)
5-min Apgar 7, n (%) 7 (8) 555 (1.3) 7 (3 - 15) < 0.001*
Birth weight (g), mean ± SD 2,913 ± 69 3,493 ± 540.5 < 0.001
Birth length (cm), mean ± SD 47.6 ± 3.6 50.8 ± 2.4 < 0.001
Small for gestational age 29 (32.6) 2,876 (6.6) 7.2 (4.6 - 11) < 0.001*
Low ponderal index 9 (10.5) 3,843 (9) 1.2 (0.6 - 2.4) 0.593*
Neonatal morbidity Congenital anomalies 7 (8) 892 (2.0) 4 (1.9 - 9.2) < 0.001*
Intracranial hemorrhage 13 (15) 1,181 (2.7) 6.4 (3.5 - 12) < 0.001*
Streptococcus B 10 (12) 719 (1.7) 8 (4 - 15) < 0.001*
Infection
Early neonatal death 5 (5.8) 243 (0.6) 11 (4.4 - 27) < 0.001*
Length of hospitalization, mean ± SD (min-max) (days) 16 ± 10
(7 - 25)
10 ± 8
(3 - 39)
0.002
*
2-test.
Mann-Whitney test.Neonatal Effects of Maternal Substance Abuse
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DISCUSSION
The results of the study indicated a 0.2%
prevalence of addicted pregnant women in the
area during the 10-year study period. The actual
number of addicts is always several times greater
than the number of those identified, however,
detection of addicted women is additionally
hampered by their tendency to conceal and deny
the problem. It has been estimated that some 900
opiate addicts present for the first ever treatment
per year in Croatia with a 1 : 1 ratio of treated to
untreated addicts, yielding an incidence of 1,800
cases per year since 1997, 400 of them female.
3
In the present study, drug addiction was
demonstrated by positive urine toxicology for
dependence substances. In 62 subjects (73%) study,
testing was performed after they admitted drug
addiction during pregnancy, delivery, or after
delivery. In the remaining 23 women (27%),
toxicology testing was indicated by the neonate
behavior indicative of maternal drug addiction.
According to the Republic of Croatia legislative,
testing for dependence substances can be
performed without the patient's consent, however,
it may be limited in daily routine by the Act on
Patient Rights, according to which the patient's
informed consent should be obtained prior to any
medical procedure including toxicological screening
for dependence substances.
17 We are fully aware
that a certain proportion of neonates born to
mothers concealing their drug addiction have thus
been unrecognized, evading target pediatric
surveillance. Croatia has a properly developed
system of treatment of pregnant addicts.
18,19 Within
the frame of this Croatian model, methadone and
buprenorphine therapy is easily available to
pregnant addicts and they are encouraged to get
regular general medical check-ups and prenatal
gynecologic care in case of HCV infection in
particular.
18 Nevertheless, this model of treatment,
now considered to be the gold standard for its
favorable impact on perinatal outcome, was used
by only 6 pregnant women on a voluntary basis
in the present study.
20-22
In our study, pregnant addicts mostly declared
to be primiparae (n = 78) but the possibility of a
number of addiction-burdened pregnancies having
terminated prematurely by induced or spontane-
ous abortion should be taken in consideration, as
also reported elsewhere.
4 In spite of appropriate
treatment modalities available during pregnancy,
pregnant addicts failed to take due care of their
health, so that 65% of them had a suboptimal
number of gynecologic examinations, 41% under-
went less than 3 US studies, and 20% had
inadequate body weight gain as a direct con-
sequence of poor nutritional status. Such a poor
level of care for one's own health is characteristic
of both heroin addicts and those continuing on
heroin along with methadone therapy.
20 In 1977,
Connaughton et al. showed that pregnant addicts
exclusively on methadone therapy had a mean of
8.2 antenatal examinations whereas those that
continued using heroin along with methadone
therapy had only 1.8 antenatal examinations,
because of their uninterrupted high-risk lifestyle.
23
In the present study, the rates of maternal HCV
(49%) and HBV (16%) carriage were consistent
with those found in Croatian injecting drug users,
and comparable with those reported elsewhere.
24,25 Although the rate of HCV vertical transmis-
sion is known to be very low as demonstrated by
studies in an Australian population (3%), it
Table 5. Incidence of Neonatal Abstinence Syndrome in Infants Born to Pregnant Addicts
Withdrawal syndrome (n) %
Pregnant addicts (n = 86) 61 71.0
Heroin addicts (n = 51) 39 76.5
Heroin and methadone addicts (n = 9) 6 -
Methadone addicts (n = 6) 4 -
Other substance dependence (n = 19) 12 63.0Mirjana Vucinovic, et al.
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eventually poses a risk of long-term morbidity
and mortality.
26 We found no case of human
immunodeficiency virus (HIV) infection in our
study population of pregnant addicts. Croatia still
has a low level of HIV epidemic, with relatively
stable epidemiological trends in recent years.
Although there is a large having a high number
of heroin injecting addicts, estimated to be more
than 10,000, systematic HIV testing of injecting
drug users seeking treatment shows a very low
prevalence of HIV infection (< 1%) since 1991. The
risk of HIV outbreak has been estimated as
moderate, in part owing to the primary and
secondary prevention actions launched for years.
24
In spite of the fact that polydrug use in
pregnancy contributes to the higher prevalence of
perinatal complications such as placental
hemorrhage, more than 90% of our pregnant
addicts had vaginal delivery. It should be noted
that there was no case of abruptio placentae,
which may have been due to the relatively small
sample of pregnant addicts (n = 85).
27 There was no
case of stillbirth either, which could be seen as an
unexpected finding considering their high-risk
lifestyle that they did not give up during
pregnancy. However, there might have been
stillbirths among pregnant addicts who kept their
addictions to themselves, thus evading identifica-
tion. Generally, children born to pregnant addicts
had a high rate of perinatal morbidity.
Preterm delivery was more common in
pregnant addicts, with drug abuse entailing a
relative risk of 3.45. Inadequate numbers of
clinical and US examinations due to poor care for
one's own health and unawareness of the risks
associated with their hazardous lifestyles may
have contributed to the increased prevalence of
premature deliveries. Premature deliveries and
SGA are the most common antenatal complica-
tions of addiction pregnancies, which can threaten
neonatal outcome irrespective of the drug
effect.
8,12,22,27,28 Although heroin is known to cross
the transplacental barrier and is associated with
low birth weight infants, we admit that this
outcome may be only partly due to the effect of
the drug itself and is also likely to be due to
associated lifestyle factors such as poor maternal
dietary habits, increased rate of maternal infection,
and reduced antenatal care attendance.
21,22
Furthermore, many investigators report that
methadone therapy in pregnant heroin users
significantly increases infant birth weight.
20,21,29,30
The currently accepted protocol for pregnant
heroin users includes methadone therapy which,
in combination with antenatal care, results in
considerable birth weight improvement.
20,23,27 Our
results pointed to rather poor acceptance of
antenatal methadone therapy.
One-third of our pregnant addicts gave birth to
SGA infants, suggesting that the addiction
lifestyle is associated with a high risk of retarded
fetal growth (RR = 5.103). Our results are consistent
with the reports in the literature.
13,21,22 Hulse et al.
found concurrent use of heroin and methadone to
reduce birth mass by 557g, similar to the effect of
heroin alone.
20 To our knowledge, the type of fetal
growth disorders in pregnant addicts has not yet
been specifically analyzed. It may seem surprising
that the probability of delivering a newborn of
low PI as a measure of symmetric growth is
identical in pregnant addicts and the general
population. Neonates born to pregnant addicts are
smaller but not thinner than those born to
non-addicts. The factors implicated in fetal growth
retardation in pregnant addicts exert their
influence throughout gestation and include infec-
tions and sexually transmitted diseases, maternal
malnutrition and inadequate body weight gain,
drug abuse, and overall addict's lifestyle.
6,12,20,27
Thus, the early gestational period predominated
by cell hyperplasia, medium gestational period
with gradual inclusion of hypertrophy in growth
determination, and the last trimester predomi-
nated by hypertrophy in fetal growth are equally
affected.
31 Therefore, symmetric growth retarda-
tion as seen in pregnant addicts is a logical result
of these events.
In our study, children born to addicted mothers
had a high prevalence of NAS (71%), mostly in
those born to heroin and methadone addicts,
which is consistent with literature data.
13 This
withdrawal syndrome is a constellation of
behavioral and physiological signs and symptoms
that are remarkably similar despite marked
differences in the causative agent properties. The
symptoms of NAS include high-pitched crying,
irritability, vomiting, diarrhea, and tremor.
2,13
Addiction or tolerance is due to passage of theNeonatal Effects of Maternal Substance Abuse
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drugs across the transplacental barrier, and this
occurs in varying degrees depending on the
pharmacokinetic properties of the particular drug.
Therefore, disruption of this transplacental
passage of drugs at birth results in the develop-
ment of withdrawal syndrome.
2 Based on
thorough social and drug history including types
of drugs used and data obtained from self-
reporting addicted mothers, these newborns were
admitted to the Neonatal Intensive Care Unit and
observed by experienced staff to detect symptoms
of withdrawal, initiate treatment before more
severe encephalopathy supervened, and collect
urine for toxicology screening. We used Finnegan's
scoring system, and pharmacotherapy with
phenobarbital was introduced when the average
of 3 scores was 8 or more.
32,33 Sarkar and Donn
report that the management of NAS widely varies
with inconsistent policies to determine its
presence and treatment.
34 There is only 1
randomized trial comparing different types of
opioid-based medications for NAS treatment, and
management of infants with NAS is still con-
troversial and hampered by the lack of evidence
from properly conducted trials.
35,36 Phenobarbital
is commonly used for the treatment of NAS. We
used it at a loading dose followed by 5 mg/kg/
day, with dosage increase/decrease according to
response in each individual case. Kaltenbach and
Finnegan found the loading dose of phenobarbital
to reduce the length of treatment if administered
as monotherapy.
35
The results of our study revealed that children
born to pregnant addicts had a higher rate of
perinatal hypoxia and diseases unrelated to
maternal addiction such as early sepsis caused by
Streptococcus agalactiae, intracranial hemorrhage,
and congenital anomalies. The high rate of early
neonatal sepsis caused by beta-hemolytic strepto-
coccus B (BHSB) is no surprise in neonates born
to mothers from high-risk groups. BHSB infection
is associated with maternal anorectal and uro-
genital colonization, chorioamnionitis, premature
delivery, and prolonged rupture of fetal
membranes.
37 Our results showed that none of the
pregnant addicts underwent prenatal testing for
BHSB. Only 1 pregnant addict with her newborn's
blood culture found to be positive for BHSB
received intrapartum antibiotic prophylaxis with a
single dose of ampicillin. Maternal risk factors for
the development of early BHSB infection were
present in 6 children (60%), and included intra-
partum fever in 4 mothers and prolonged rupture
of fetal membranes in 2 mothers. One infant died
from early BHSB sepsis on the fourth day of life.
Although opiate abuse is not directly associated
with an increased prevalence of cardiac defects,
these congenital anomalies were most common in
our study population.
13,27 Congenital cardiac
defects accounted for a significant proportion of
neonatal mortality, which was very high in
comparison with the control group.
The present study confirmed the problem of
addiction in Croatia and pointed to a distur-
bingly low proportion of pregnant addicts being
included in the system of institutional care and
surveillance. The study period covered the early
postwar period, but, it could only in part explain
the low level of institutionalized care for pre-
gnant addicts. The management of this high-risk
group requires proper organization as it is time-
consuming, uncertain, and expensive. Obviously,
additional efforts should be invested in the care
for this high-risk group of women because the
problem of their addiction is transmitted to their
offspring. Children born to addicted mothers are
faced not only with withdrawal syndrome but
also have a significantly higher risk of neonatal
morbidity and mortality.
6,13,27 Like other authors,
we could not differentiate the direct con-
sequences of drug abuse from a number of other
unfavorable medical and social factors closely
associated with poor lifestyle and habits of
pregnant addicts.
20,27 In our setting, methadone
therapy as a currently accepted treatment modality
for pregnant addicts has not yet taken hold since
it was used by 6 women only. We are fully
aware that methadone therapy is far from ideal
due to the high likelihood of NAS development
recorded in 63 - 85% newborns exposed to
maternal methadone therapy yet it remains the
predominant treatment modality that may
improve perinatal outcome by careful drug
titration and organized approach in the surveil-
lance and control of addiction pregnancies.
13,38
Addicted mothers are aware that the quality of
their children's care upon discharge from the
maternal ward is questionable, and this issueMirjana Vucinovic, et al.
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calls for active involvement of various services;
first of all, social welfare institutions. These
women tend to keep their addiction secret for
fear of being deprived of custody of the child
and of their addiction disclosure, which in turn
has adverse effects on pregnancy outcome.
During the 10-year study period, 5 children born
to 3 mothers were placed at a social welfare
institution. In these cases, maternal addiction was
additionally burdened with psychiatric comor-
bidity.
An inherent weakness of this study was the
self-reported nature of the data. It is difficult to
elicit valid information on illicit drug abuse, and
under-reporting is a common problem. We believe
that patients included in the study were
reasonably candid about their self-reported drug
abuse because medical record information was
confirmed by urine toxicology. Unfortunately, we
do not have information on pregnancies delivered
elsewhere, however, this is a county hospital and
the majority of narcotics users probably gave birth
here. We are aware that the real number of
narcotics-dependent pregnant women having
delivered during the study period must have been
considerably higher.
The problem of opiate dependence poses a
major problem in our area, and the results of the
present study of pregnancy outcome and neonatal
fate in this population during the 10-year period
point to inadequate systematic organization of
care for pregnant addicts with high-risk pre-
gnancy while their newborns suffer from medical
and social consequences of maternal addiction.
Although there is no ideal treatment modality for
pregnant addicts, this vulnerable population
group obviously requires systematic and
organized care. It is a relatively small but specific
group of pregnant women who pose an intriguing
perinatological problem due to the high incidence
of complications, yet with a potentially successful
active approach.
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